公开(公告)号：US20150133428A1

公开(公告)日：2015-05-14

申请号：US14541343

申请日：2014-11-14

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Upender Velaparthi ,  Chetan Padmakar Darne ,  Peiying Liu ,  Mark D. Wittman ,  Bradley C. Pearce ,  Erika M. V. Araujo ,  Bireshwar Dasgupta ,  Jalathi Surendran Nair ,  Sakthi Kumaran Janakiraman ,  Chandrasekhar Reddy Rachamreddy ,  Mettu Mallikarjuna Rao ,  Arul Mozhi Selvan Subbiah Karuppiah ,  Bandreddy Subba Reddy ,  Pulicharla Nagalakshmi ,  Rajesh Onkardas Bora ,  Shilpa Holehatti Maheshwarappa ,  Selvakumar Kumaravel ,  Dibakar Mullick ,  Ramesh Sistla

IPC: C07D487/04 ,  C07D487/10 ,  C07D491/20 ,  C07D491/147

CPC classification number: C07D487/04 ,  C07D487/10 ,  C07D487/20 ,  C07D491/147 ,  C07D491/20 ,  C07D519/00

Abstract: The invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents.

Abstract translation: 本发明提供式（I）化合物及其药学上可接受的盐。 式（I）的化合物抑制蛋白激酶活性，从而使它们用作抗癌剂。

公开(公告)号：US20140235647A1

公开(公告)日：2014-08-21

申请号：US14347893

申请日：2012-09-27

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： James Aaron Balog ,  Audris Huang ,  Upender Velaparthi ,  Peiying Liu

IPC: C07D487/04 ,  C07D417/14 ,  C07D413/14 ,  C07D413/06 ,  C07D471/04

CPC classification number: C07D498/04 ,  C07D409/04 ,  C07D409/14 ,  C07D413/04 ,  C07D413/06 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D495/04 ,  C07D519/00

Abstract: Disclosed are azaindazole compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein: X is O and Y is N; or X is S and Y is CH; Z is CR2 or N; Q is a heteroaryl; and R1 is defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.

Abstract translation: 公开了式（I）的氮杂吲唑化合物或其药学上可接受的盐，其中：X为O且Y为N; 或X为S，Y为CH; Z是CR2或N; Q是杂芳基; 并且R1在本文中定义。 还公开了使用这些化合物治疗至少一种CYP17相关病症例如癌症的方法，以及包含这些化合物的药物组合物。